Coordination comittee

PDF version

From the PTEMI constitution date, the PTEMI Coordination Committee meets periodically in order to achieve the following objectives:

  • Development of PTEMI strategic action lines. Implement the periodical action plan and tracking and control of planned actions.

  • Advertise the platform: The comittee organizes the advertisement tasks for the platform through traditional media, mailings, web page, platform logo, etc …

  • Funding: The comittee activity, as well as the platform in general is needed of funding. Part of which is demanded through the present project.

  • Manage, organize and administer the platform.

  • Represent the platform everywhere either in front of the institutions or the general public.

  • Act as a negotiator in front of the european management organism.

The PTEMI'S Coordination Committee is composed in parital form by public sector representatives (7 members) and private (7 members). It can advice about and develop the strategic action lines of the Platform, as well as participate in advertisement activities. Two of its members: Javier Urzay and Ferran Sanz act as co-presidents of the Coordination Comittee

Both Co-presidents y the person asigned to their secretary are responsible for the day-to-day management of the Platform, support and update the annual work plan, adapting it to the possible variations and modifying it when needed in order to achieve the stablished objectives. Moreover, they are also responsible of the tracking and control of the tasks and reporting to the delegating authorities assigned as interlocutors by the National Plan of I+D+i

The committee meets regularly at least twice a year. When it is considered convenient, Ministers, ISCIII and CDTI delegates are invited.

The Coordination Committee composition and its relation with the tecnical secretary is described in the next figure.

Following some brief CV's of each of the PTEMI Coordination Committee members are presented.

Javier Urzay

Javier Urzay

Economist from the Universidad Autónoma of Madrid and MBA from the Instituto Adriano Olivetti of Ancona (Italy), has worked as enterprise strategic consultant in DBK (Databank Group) and has been General Subdirector of Technological Services and Technology Transfer in the Centro para el Desarrollo Tecnológico Industrial (CDTI), I+D promotion agency of the Ministry of Industry, Tourism and Commerce, until 2001, date when he entered FARMAINDUSTRIA as Director of Coordination, Studies and Associate Service. Nowadays he holds the position of General Subdirector of FARMAINDUSTRIA, working primary in economical, strategic and research tasks, as well as general tasks of coordination department . Javier Urzay coordinates the industry representation in the Plataforma Tecnológica Española de Medicamentos Innovadores.

Ferran Sanz

Ferran Sanz

Professor of Biostatistics and Biomedical Informatics at the Universitat Pompeu Fabra (UPF, Barcelona) and director of the IMIM-UPF joint Research Programme on Biomedical Informatics (GRIB, http://grib.upf.edu/). He authored more than 130 articles in ISI-indexed journals and supervised 18 PhD theses. He led nine EU-funded initiatives, as well as a STOA report for the European Parliament. Currently, he is coordinating an H2020 project on the translational and clinical application of Bioinformatics (MedBioinformatics), and is the academic coordinator of an IMI (Innovative Medicines Initiative) project on the in silico prediction of drug toxicity (eTOX). He is also partner in other ongoing IMI (EMIF, iPiE and TransQST) and H2020 projects (EU-ToxRisk and ELIXIR-EXCELERATE). Ferran Sanz is academic coordinator of the Spanish Technology Platform on Innovative Medicines (PTEMI) and vice-president of Bioinformatics Barcelona (BIB). He also coordinates the Biomedical Informatics Node of the Spanish Institute of Bioinformatics (INB). He was president of the European Federation for Medicinal Chemistry (EFMC) from January 2003 to December 2005 and vice-rector for Scientific Policy of the UPF from January 2004 to March 2009.

 

Juan Álvarez 

Juan Álvarez

Juan Alvarez Bravo has a MD and PhD (Cum Laude) degree from Universidad Complutense of Madrid and PhD in Pharmacy from Tokio University with several scientific papers. He also obtained a Master in Pharmaceutical Marketing at Instituto de Empresa de Madrid. In 1995 he started his professional career in Business Development and Health Economy department at Schering Plough, developing his work in several areas, anti-infective, cardiovascular, gynecological, and multiple sclerosis. In 1996, he joined the Wyeth Farma team in the position of Medical Manager in the Antibiotics and Vaccines area. One year later, he added Rheumatology Management to his responsibilities, and in 2000 he was appointed Regional Expert in Anti-infective Diseases for Europe, Africa and the Middle East. That year he was promoted to Group Medical Manager for the Antibiotics and Vaccines Department. In 2002, he was appointed Wyeth Farma Medical Director for Spain, where he continued until he joined Pfizer as Medical Director, a job he has held until the present.

 

Cristina Avendaño Solá 

Cristina Avendaño Solá

She is a Clinical Pharmacology Specialist and Medicine Doctor (MD), and currently Head of Clinical Pharmacology at the University Hospital Puerta de Hierro. Associate Professor of Clinical Pharmacology at Universidad Autónoma de Madrid. Moreover, she is the Spanish Society of Clinical Pharmacology President, as well as the Research Ethics Committee of Puerta de Hierro Hospital President, and Sub-coordinator of SCReN platform of the Carlos III Health Institute to support clinical research and clinical trials. She is currently a European co-coordinator of ORTHOUNION project, funded by H2020 (2017-2021) and an active member of the IMI2 evaluation panel. She has focused her professional career mainly at research, evaluation and regulatory aspects of medicines. From 1995 to 2010 she held several scientific positions at the European Medicines Agency (EMA) and was also a member of its Board of Directors. She was a member of the initial Scientific Committee of IMI. She was director of the Spanish Agency of Medicines (2006-2010).

 Francisco Javier Carné Cladellas

Francisco Javier Carné Cladellas

Medical Doctor from the Universidad Autónoma de Barcelona, Specialist in clinical pharmacology. He has been a professor in the Pharmacology Department at the Universidad Autónoma de Barcelona and, during the 1990's, advisor for the Department of Pharmacy and Healthcare Products at the Ministry of Health and Consumer Affairs and member of the National Committee for the Evaluation of Medicines (CONEM). Since 1995 he is the expert advisor in medicine effectiveness and safety for the European Agency for the Evaluation of Medicinal Products (EMEA). He is also a member of the National Clinical Pharmacology Committee. Since 2000 he is the Service Manager for the Clinicla Pharmacology Unit at the Hospital Clínic i Provincial de Barcelona. He is currently the Spanish Representative for the European Clinical Research Infrastructure Netwoek (ECRIN) and the chairman of the Evaluation Committee for Medicines for Human Use (CODEM) at the Spanish Agency for Medical and Healthcare Products (AEMPS).

 Vicente Castell

Vicente Castell

Doctor of Science, Medical Doctor and Graduate in Pharmacy. Professor of Biochemistry and Molecular Biology in the School of Medicine at the Universidad de Valencia.  He has been a professor at the Universidad Autónoma de Madrid and at the University of Freiburg (Germany).  Doctorate studies at the CSIC, Federal Politechnic Institute of Zürich (ETH) and the Max-Plank Institut für Biophysikalische Chemie (Göttingen). Head of the Experimental Hepatology Unit, Research Centre at the Hospital Universitario La Fe de Valencia (1980). Eurpoean Award for Pharmaceutical Research (EFPIA) at the University of Heidelberg (1990). Director of the Foundation for Research at the H.U. La Fe, main area of research in hepatotoxicity mechanims due to drugs.  Author of 350 scientific works, 15 reviews and two books. He has participated as head researcher in 30 national projects  and 10 for the Eruopean Union, acting as coordinator on two occasions. Consultant for various national (FIS, PN I+D, CICYT) and international (COLIPA, ILSI INVITOX, ECVAM, DGXII/EU) institutions and agencies.  Founding member of the spin-off "Advancell, S.L.".
Javier Fernández Gadea

Javier Fernández Gadea

Doctor in Chemical Sciences from the Universidad Complutense de Madrid 1980. In 1985 he entered in Janssen and Cilag Spain to start up the Medicinal Chemistry Department. In 1990 he was promoted to Head of Medicinal Chemistry at Centro de Investigación Básica de Toledo being apponinted as Director of these centre in 2000. By 2003 he was promoted to Research Fellow of Jhonson & Jhonson and he became a full member of Management Board of Janssen-Cilag España. He leads projects in a wide variety of therapeutics areas since 1985, resulting in 14 NME's (New Molecular Entity) that entered clinical developmento so far. He is co-author of over 40 publications, 25 oral communications and invited lectures, and co-inventor in over 30 international patent applications. He is regular paricipant in Master and Doctorade Courses at several universities throughout Spain. Director of two doctoral theses and he has participated as invited jury member in the evaluation of 14 doctoral theses. He is a member of the Executive Committee of the Europen Federation of Medicinal Chemistry (EFMC) and Vice-president of the Spanish Royal Society of Therapeutic Chemistry (SEQT). He is also member of the Royal Spanish Society of Chemistry and of the Specialized Group of Organic Chemistry of this society. He has established in Spain through the participation of Hanssen-Cilag two scientific research prizes in different areas.

Andrés G. Fernández

Andrés G. Fernández

PhD (Pharmacology; Univ. Barcelona) and MS (Pharmacy Spec. Biochemistry; Univ. Barcelona). Current position: Director of Ferrer Advanced Biotherapeutics at Ferrer. Previous positions: Biotechnology and Biological Sciences, Director (Ferrer); R&D Director & Member of the Board (Salvat); Associate Director of Discovery (Almirall); Associate Professor Cell Biology (UAB); Head of Pharmacology (Almirall). Direct executive and scientific responsibilities on teams successfully developing and launching: 5 New Molecular Entities (EU/USA/ASIA); 1 New Therapeutic Entity in USA/EU and 1 New Molecular DX product in EU. Co-author of over 40 peer-review publications, 110 communications and lectures and co-inventor of 18 international patent applications. Director of two doctoral theses. Former Chairman of the Program Committee of the International Union of Pharmacology (IUPHAR). Member of the Board of Directors of ASEBIO. Chair of the Catalan Society of Medical Biotechnology. Mentor in CaixaImpulse Programme. Member of the Scientific Advisory Board at BIONAND. Member of the Scientific Committee of multiple Congresses and Meetings. Member of the Jury of various Scientific Awards. Frequent Invited Speaker at many Scientific or Academic events. Current interests: Open innovation & Collaborative Bio-Research. Advanced Therapies. Neuropharmacology. Ophthalmology. Molecular diagnostics. Research policies & sustainability.

Jesús Hernández

Estrella García

Science degree (1998) and PhD IN Genetic Toxicology “Cum Laude” by the University of Navarra in 1991. Estrella held at post-doctoral position at ICI (now Astra Zeneca) in Macclesfield, UK. Subsequently Estrella returned to Spain where she joined Almirall as a Clinical Research Scientist. Since then, Estrella has amassed a 25 year career with the company- taking on roles of increasing demand and responsibility, including Head of Allergy Therapeutic Area and Head of Clinical Development Operations- to the role she holds today, Director Global Clinical Operations. She has been responsible for ensuring Clinical Development for several anti-inflammatory compounds, in the respiratory and pain arena, like ebastine/pseudofedrine, almmotriptan and aclidinium bromide. They are available in the EU and US, and in other markets. She also has contributed to the development of Actikerall® in Actinic Keratosis and Dimetilfumarate (Skilarence® ) for Psoriasis available now in EU (2017). Executive Women Management Course in ESADE Business & Law School, 2015. Since them she is the Site Coordinator of Polichem, the company acquired by Almirall in that year. She also her team distributed in all 3 R&D sites, Sant Feliu De LLobregat (Spain), Reinbek (Germany) and Lugano (Switzerland).

Jesús Hernández

Jesús María Hernández Rivas

Jesús María Hernández Rivas holds a PhD in Medicine and Surgery from the University of Salamanca, where he is professor of Haematology. He is also a specialist in Haematology and Haemotherapy at the University Hospital of Salamanca. For more than two decades, he has led the Oncology Citogenetic Unit (UCO) as part of the Haematology Service at the hospital, a centre of reference for citogenetic studies of Castile and León, as well as Aragon, Extremadura and Andalusia. He leads the “Molecular genetics in Oncology” research group at Cancer Research Centre and Salamanca Biomedicine Research Institute (IBSAL). He has published more than 200 papers in international scientific journals, led more than 50 research projects and 15 doctoral theses. He also led EUGESMA concerted action “Translating genomic and apigenetic studies of MDS and AM”, a study which combines analysis on expression profiling, exon arrays, genome analysis and methylation in MSD and AML. Moreover, he has been a member of the executive committee of the concerted action sponsored by the Marie-Curie Foundation “CGH arrays and Molecular Cytogenetics”. He has been part of international projects, such as IRON, ELAN (Europan Study for the Evaluation on NGS in Leukemia Diagnostics) and NGS-PTL “Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia”, of FP7-HEALTH-2012INNOVATION-1 project, whose goal is to establish a translational “diagnosis panel for leukemia”, that includes the most relevant molecular biomarkers for diagnosis and prognostic in order to simplify clinical decision making. Currently, he coordinates the HARMONY project, which is integrated in “Big Data for Better Outcomes,” an IMI Programme (Innovative Medicines Initiative) of the EU (IMI2-2015-06-04 - Development of an outcomefocused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies) of the call "H2020-JTI-IMI2-2015-06-twostage".

 Arturo López

Arturo López Gil

An experienced Pharmaceutical Physician with National & International Experience and more than 20 years of growing responsibility in positions at both Affiliate and Headquarters settings. I am a certified MD with a PhD and a certified Clinical Pharmacology Specialist. My professional experience spans all the medicinal product life cycle from early (Phase I/II) and late clinical development (Phase II/IV) to Medical Affairs and post marketing support, including the launch of specialized products. I am passionate about Medical Affairs (Medical Strategy, External Expert engagement, Evidence Generation and Dissemination and Medical Education), with extensive experience in Clinical Research and Clinical Operations Phases I-IV, Regulatory/Promotion and Management of large teams. I have a passion and an appetite for building, co-creation, process improvement, change management, team development, and above all, for medical/scientific strategy and innovation. I have built my professional career around a wide array of therapeutic areas, the ones that provide more benefits to patients with unmet needs: Internal Medicine, Neurology, Immunology (Derma, Gastro, Rheum), Rare Diseases, Oncology (emesis) and anti-Infective/antivirals (HCV).

Mabel Loza

Mabel Loza

Doctor in Pharmacy from the Universidad de Santiago de Compostela (USC). Senior Lecturer in Pharmacology at the USC, where she leads a research and researching staff training group.  In the area of projects applied to medicine R&D, she is the author of six patents at different stages of procesing.  In the area of public research, she has authored over 60 publications in the journals with the greates influence in the area.  She has directed 8 doctoral theses and 28 postgraduate research works.  She participates continually in national and international conferences. She is an evaluator on research projects for national and European Institutions. She has taken part in 35 research projects financed with funding from the public and private institutions.  She has promoted the creation of a company (Pharmatool Digital Interactive), the creation of the USEF Platform for screening drugs and BIOPHARMA Group for translational research in psychiatry in Galicia.

Fernando Peláez

Fernando Peláez

Bachelor’s Degree in Biology from the Universidad Complutense de Madrid in 1984 and carried out his PhD studies at the Centro de Biología Molecular (Universidad Autónoma de Madrid). In 1989 he joined the Centro de Investigación Básica de España (CIBE) - the basic research site of Merck, Sharp & Dohme in Spain, where he was responsible for fungal research within a screening group dedicated to discovering natural products with biological activity as a source of new leads in drug development. During this time he contributed to the discovery of many new molecules with therapeutic potential - some of which have progressed to different developmental stages as future drugs. Appointed as CIBE Director in 1999, he led a department with a staffing of 70 people for nine years; during this time he expanded his responsibilities within the company to cover other areas within the drug discovery process. Thus, his group also supported lead optimization projects carried out in other Merck research sites by implementing in vitro automated screens to assess safety and potential drug-drug interactions of candidate molecules. In December 2008 he joined the Spanish National Cancer Research Center (CNIO) as Director of the Biotechnology Programme, where he supervises the Core Units that provide CNIO research groups with access to a broad spectrum of cutting-edge technologies, including genomics, proteomics, transgenic mouse generation, inmunohistochemistry, molecular imaging and several others. Since October 2011 he is also the Head of the CNIO Director's Office. Fernando Peláez is author or co-author of 130 original papers, reviews and book chapters, and co-inventor of more than 40 patents on bioactive natural molecules. Since July 2014 he is Vicepresident of the Spanish Society of Biotechnology (SEBIOT)

 

Antonio Portolés

Medical Doctor and Specialistin Clinical Pharmacology. PostgraduateDiplomainDesignandStatisticsinHealth Sciences. TrainingandQualityManagement. Professional Experience: Chief of SectionofClinical PharmacologyExtensive experience indesign,evaluation andresearch development. He has elaborated researchinallphasesofdevelopment and use ofdrugs,especiallyintheearly stages(phase I) TeachingandResearchExperience: Associate Professor,UniversityComplutenseofMadridanddirectorof doctoral theses.Numerous articles injournals, conferencesandbooks, co-editor of severalbooks.

Eduard Valentí

Eduard Valentí

Doctor in Chemical Sciences from the Universidad de Barcelona. Master in Business Management an Administration from ESADE and graduated of General Management Programme from the IESE.  For four years he worked as an educator in the Organic Chemistry departement at the Universidad de Barcelona. In 1988 he joined Laboratorios Dr.Esteve as manager of the Moleculas Modelling Unit. From 1993 to the present he has been the R&D Management Director at he laboratories. Likewise, he has authored 29 scientific publications and communications at international conferences and he has given 30 lectures and courses in the field of research management.


 Jose Manuel Vázquez Rodríguez 

Graduated in Medicine and Surgery at the University of Santiago de Compostela (1986). Specialist in Cardiology (1995). Doctor of Medicine, University of A Coruña (2010). Postgraduate courses in basic statistics, advanced statistics and research design (1997, Autonomous University of Barcelona). Master in Health Care Systems Management (2006, University of A Coruña). Certified in Management of Integrated Health Care Services (2011, ESADE Business School). In 1990 he began his training MIR in Cardiology in the Hospital Juan Canalejo of A Coruña. In 1994, was invited for six months to St. George's Hospital Medical School in London as a fellow of the Cardiological sciences department. In 1995 he joined the Unit of Cardiac Catheterization and Interventional Cardiology at the Hospital Juan Canalejo. Between 2001 and 2005 he was tutor of residents in Cardiology and member of the Continuing Medical Education Committee of the Spanish Society of Cardiology. Between 2006 and 2007 he was Medical Director of the University Hospital Juan Canalejo. Between 2009 and 2012 Director of Organization and Clinical Management at the University Hospital A Coruña, assuming responsibilities for teaching, research management and quality management as well as care management tasks. Since 2012 he is Coordinator of Teaching and R & D in the Health Care Area of A Coruña. Since December 2012 he is General Director of the Institute of Biomedical Research of A Coruña (INIBIC). Since June 2012 is the President of the Galician Society of Cardiology. Author or coauthor of 75 scientific articles and collaborator of web portals specialized in medicine

 

 

Amelia Martín Uranga

Amelia Martín Uranga

Graduated in Law from Deusto University and doctorate in Law, with a thesis on legal protection of biotechnology innovations. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination of  the “BEST” Project, as a strategic initiative promoted by the pharmaceutical industry with the aim of integrating all stakeholders, both public and private, to create an excellence based platform for clinical research in Spain. The objective is to boost R&D investment through monitoring the situation of the spanish Clinical Research process ;  identifying  the different practices and taking actions to improve  the efficiency and competitiveness position  in this field. This is a project made of more than 40 pharmaceutical companies executing over  90% of the clinical research promoted by the Spanish industry, 57 hospitals and 12 Regions in Spain. She also manages different biomedical research promotion programs such as the coordination of the Pharma-Biotech programme  being part of a public-private cooperation programs to promote the R&D of new drugs. She also coordinates different clinical trials working groups at FARMAINDUSTRIA.


She participates, as key note speaker, in numerous international and national Congresses, Seminars and Events in relation with clinical trial regulation ie.;CAEME (Cámara Argentina de Especialidades Médicas), BEST Project, and IMI.


Furthermore, she is an active member of Inovative Medicines Initiative Forum in Spain, not only to promote the Spanish participation in different IMI calls but to also make the IMI rules and procedures Known to different stakeholders.


She has a broad professional experience of more than 15 years teaching graduated and post graduated courses related with legal aspects in Biomedicine in prestigious national and international universities. She has developed her research work in the Interuniversity Chair in Law and the Human Genome -of which she is a scientific advisor, the UNED and the Sheffield Institute of Biotechnological Law and Ethics in the Sheffield University (UK). She has published several papers on legal aspects of Biomedicine.

Technical Secretary

Its principal mission is to support the Coordination Committee in day to day work. The Technical Secretary is located in the office that the PTEMI has in the Farmaindustria headquarters and has the personnel and infraestructure needed to acomplish its function.

The main functions of the Technical Secretary consist of:

  • Provide support to the Coordination Committee in the day to day management.
  • Maintain and update the web page of the PTEMI.
  • Write and distribute the Newsletter of the PTEMI.
  • Coordinate the organization of the Annual conferences and other events planned by the PTEMI.
  • Serve the working groups and participants of the PTEMI and transmit to the Coordination Committee the initiatives that emerge from the Participants Forum.
  • Represent the PTEMI in the designated events.
  • Report to the organizations involved in the PTEMI activities, particularly the MINISTERIO DE CIENCIA E INNOVACIÓN.

From the PTEMI foundation the management of the Technical Secretary is responsibility of Amelia Martín Uranga.

Esta página web se realizó en 2009 con apoyo financiero del Ministerio de Ciencia e Innovación y de los Fondos FEDER. Dentro del PN de investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011. Ref. RET-90000-2008-001